LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Celldex Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

20.27 -4.21

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

20.12

Max

21.38

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.7M

-54M

Verkäufe

-480K

695K

EPS

-0.81

Gewinnspanne

-7,740.432

Angestellte

186

EBITDA

-6.7M

-62M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+156.45% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

6.8M

1.4B

Vorheriger Eröffnungskurs

24.48

Vorheriger Schlusskurs

20.27

Nachrichtenstimmung

By Acuity

50%

50%

154 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Celldex Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Juni 2025, 20:51 UTC

Ergebnisse

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. Juni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Juni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. Juni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. Juni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. Juni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Juni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. Juni 2025, 18:39 UTC

Market Talk
Ergebnisse

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. Juni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. Juni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. Juni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. Juni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. Juni 2025, 17:08 UTC

Ergebnisse

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. Juni 2025, 16:52 UTC

Akquisitionen, Fusionen, Übernahmen

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. Juni 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. Juni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. Juni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Peer-Vergleich

Kursveränderung

Celldex Therapeutics Inc Prognose

Kursziel

By TipRanks

156.45% Vorteil

12-Monats-Prognose

Durchschnitt 54.29 USD  156.45%

Hoch 74 USD

Tief 38 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Celldex Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

9

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

18.91 / 20.63Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

154 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.